Sweden’s Sobi Agrees Merger with CTI BioPharma
Swedish Orphan Biovitrum (Sobi) has agreed a merger with CTI BioPharma, a US biopharmaceutical company focused on blood-related cancers and rare diseases. Through a wholly owned, indirect subsidiary, Sobi plans to commence a cash tender offer that values CTI at $1.7 billion.
